Premium
Use of Argatroban during multi‐organ procurement: pharmacokinetics and sequelae in recipient of transplanted liver
Author(s) -
Schwartz J.J.,
Hatch J.M.,
Book Z.,
Lonardo N.,
Hutson W.R.,
Sorensen J.B.
Publication year - 2009
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2009.01042.x
Subject(s) - medicine , organ procurement , argatroban , coagulopathy , bolus (digestion) , pharmacokinetics , gambit , procurement , direct thrombin inhibitor , liver transplantation , intensive care medicine , pharmacology , transplantation , surgery , thrombin , warfarin , platelet , fluent , computer simulation , dabigatran , marketing , engineering , business , atrial fibrillation , simulation
This report illustrates potential concerns regarding the administration of Argatroban (AGN), a small molecule, direct thrombin inhibitor, within the setting of multi‐organ procurement (MOP). Herein, we outline the case of a large AGN bolus to the donor during MOP, and the passive transfer of a coagulopathy to the recipient of the transplanted liver. From this, we conclude that caution should be exercised when AGN is used in the setting of MOP.